Stem cell (SC) therapy has become a potential treatment modality for pulmonary artery hypertension (PAH), but the efficacy of human SC and priming effects have not yet been established. The mobilization and homing of hematopoietic stem cells (HSCs) are modulated by priming factors that include a bioactive lipid, sphingosine-1-phosphate (S1P), which stimulates CXCR4 receptor kinase signaling. Here, we show that priming human mesenchymal stem cells (MSCs) with S1P enhances their therapeutic efficacy in PAH. Human MSCs, similar to HSCs, showed stronger chemoattraction to S1P in transwell assays. Concomitantly, MSCs treated with 0.2 μM S1P showed increased phosphorylation of both MAPKp42/44 and AKT protein compared with nonprimed MSCs. Furthermore, S1P-primed MSCs potentiated colony forming unit-fibroblast, anti-inflammatory, and angiogenic activities of MSCs in culture. In a PAH animal model induced by subcutaneously injected monocrotaline, administration of human cord blood-derived MSCs (hCB-MSCs) or S1P-primed cells significantly attenuated the elevated right ventricular systolic pressure. Notably, S1P-primed CB-MSCs, but not unprimed hCB-MSCs, also elicited a significant reduction in the right ventricular weight ratio and pulmonary vascular wall thickness. S1P-primed MSCs enhanced the expression of several genes responsible for stem cell trafficking and angiogenesis, increasing the density of blood vessels in the damaged lungs. Thus, this study demonstrates that human MSCs have potential utility for the treatment of PAH, and that S1P priming increases the effects of SC therapy by enhancing cardiac and vascular remodeling. By optimizing this protocol in future studies, SC therapy might form a basis for clinical trials to treat human PAH.
Get full access to this article
View all access options for this article.
References
1.
GalieN, HoeperMM, HumbertM, TorbickiA, VachieryJL, BarberaJA, et al. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 30:2493–2537.
2.
D'AlonzoGE, BarstRJ, AyresSM, BergofskyEH, BrundageBH, DetreKM, et al. (1991). Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 115:343–349.
3.
ChannickRN, SimonneauG, SitbonO, RobbinsIM, FrostA, TapsonVF, et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 358:1119–1123.
4.
OlschewskiH, SimonneauG, GalieN, HigenbottamT, NaeijeR, RubinLJ, et al. (2002). Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 347:322–329.
5.
SimonneauG, BarstRJ, GalieN, NaeijeR, RichS, BourgeRC, et al. (2002). Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 165:800–804.
6.
GalieN, BadeschD, OudizR, SimonneauG, McGoonMD, KeoghAM, et al. (2005). Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 46:529–535.
7.
GalieN, GhofraniHA, TorbickiA, BarstRJ, RubinLJ, BadeschD, et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353:2148–2157.
8.
PulidoT, AdzerikhoI, ChannickRN, DelcroixM, GalieN, GhofraniHA, et al. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 369:809–818.
9.
BenzaRL, MillerDP, BarstRJ, BadeschDB, FrostAE and McGoonMD. (2012). An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest, 142:448–456.
10.
WangCH, CherngWJ, YangNI, KuoLT, HsuCM, YehHI, et al. (2008). Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol, 28:54–60.
MinguellJJ, AllersC and LasalaGP. (2013). Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev, 22:193–203.
13.
TashiroK, NonakaA, HirataN, YamaguchiT, MizuguchiH and KawabataK. (2014). Plasma elevation of vascular endothelial growth factor leads to the reduction of mouse hematopoietic and mesenchymal stem/progenitor cells in the bone marrow. Stem Cells Dev, 23:2202–2210.
14.
KarapetyanAV, KlyachkinYM, SelimS, SunkaraM, ZiadaKM, CohenDA, et al. (2013). Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev, 22:1645–1656.
15.
GnecchiM, ZhangZ, NiA and DzauVJ. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res, 103:1204–1219.
16.
GnecchiM, HeH, NoiseuxN, LiangOD, ZhangL, MorelloF, et al. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J, 20:661–669.
17.
BaberSR, DengW, MasterRG, BunnellBA, TaylorBK, MurthySN, et al. (2007). Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol, 292:H1120–H1128.
18.
ZhangZH, LuY, LuanY and ZhaoJJ. (2012). Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension. Exp Ther Med, 4:839–843.
19.
FarberHW and LoscalzoJ. (2004). Pulmonary arterial hypertension. N Engl J Med, 351:1655–1665.
20.
FadiniGP, AvogaroA, FerraccioliG and AgostiniC. (2010). Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J, 35:418–425.
21.
PriceLC, WortSJ, PerrosF, DorfmüllerP, HuertasA, MontaniD, et al. (2012). Inflammation in pulmonary arterial hypertension. Chest, 141:210–221.
22.
JiangY, JahagirdarBN, ReinhardtRL, SchwartzRE, KeeneCD, Ortiz-GonzalezXR, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418:41–49.
23.
OswaldJ, BoxbergerS, JorgensenB, FeldmannS, EhningerG, BornhauserM, et al. (2004). Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells, 22:377–384.
24.
GehrkeI, GandhirajanRK, Poll-WolbeckSJ, HallekM and KreuzerKA. (2011). Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med, 17:619–627.
25.
OrtizLA, GambelliF, McBrideC, GauppD, BaddooM, KaminskiN, et al. (2003). Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A, 100:8407–8411.
26.
XuJ, WoodsCR, MoraAL, JoodiR, BrighamKL, IyerS, et al. (2007). Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol, 293:L131–L141.
27.
RatajczakMZ, Zuba-SurmaE, KuciaM, RecaR, WojakowskiW and RatajczakJ. (2006). The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia, 20:1915–1924.
28.
KuciaM, RecaR, MiekusK, WanzeckJ, WojakowskiW, Janowska-WieczorekA, et al. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-CXCR1–CXCR4 axis. Stem Cells, 23:879–894.
29.
TsuzukiY, FukumuraD, OosthuyseB, KoikeC, CarmelietP and JainRK. (2000). Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha→hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res, 60:6248–6252.
30.
MorikawaS, MabuchiY, KubotaY, NagaiY, NiibeK, HiratsuE, et al. (2009). Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med, 206:2483–2496.
31.
CorpechotC, BarbuV, WendumD, ChignardN, HoussetC, PouponR, et al. (2002). Hepatocyte growth factor and c-met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol, 160:613–620.
32.
KuciaM, ZhangYP, RecaR, WysoczynskiM, MachalinskiB, MajkaM, et al. (2005). Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia, 20:18–28.
33.
RatajczakMZ, KimCH, WojakowskiW, Janowska-WieczorekA, KuciaM and RatajczakJ. (2010). Innate immunity as orchestrator of stem cell mobilization. Leukemia, 24:1667–1675.
34.
RatajczakMZ, LeeH, WysoczynskiM, WanW, MarliczW, LaughlinMJ, et al. (2010). Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia, 24:976–985.
35.
KimCH, WuW, WysoczynskiM, Abdel-LatifA, SunkaraM, MorrisA, et al. (2012). Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia, 26:106–116.
36.
KimC, SchneiderG, Abdel-LatifA, MierzejewskaK, SunkaraM, BorkowskaS, et al. (2013). Ceramide-1-phosphate regulates migration of multipotent stromal cells and endothelial progenitor cells—implications for tissue regeneration. Stem Cells, 31:500–510.
37.
RecaR, CramerD, YanJ, LaughlinMJ, Janowska-WieczorekA, RatajczakJ, et al. (2007). A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins. Stem Cells, 25:3093–3100.
38.
RatajczakJ, RecaR, KuciaM, MajkaM, AllendorfDJ, BaranJT, et al. (2004). Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood, 103:2071–2078.
39.
WuW, KimCH, LiuR, KuciaM, MarliczW, GrecoN, et al. (2012). The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantation. Leukemia, 26:736–745.
40.
LeeHM, WuW, WysoczynskiM, LiuR, Zuba-SurmaEK, KuciaM, et al. (2009). Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia, 23:2052–2062.
41.
ChenJ, TangH, SysolJR, Moreno-VinascoL, ShiouraKM, ChenT, et al. (2014). The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med, 190:1032–1043.
42.
RhodesCJ, HowardLS, BusbridgeM, AshbyD, KondiliE, GibbsJSR, et al. (2011). Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol, 58:300–309.
43.
SongM, HeoJ, ChunJY, BaeHS, KangJW, KangH, et al. (2014). The paracrine effects of mesenchymal stem cells stimulate the regeneration capacity of endogenous stem cells in the repair of a bladder-outlet-obstruction-induced overactive bladder. Stem Cells Dev, 23:654–663.
44.
LeeM, JeongSY, HaJ, KimM, JinHJ, KwonS-J, et al. (2014). Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem Biophys Res Commun, 446:983–989.
45.
JangYK, KimM, LeeY-H, OhW, YangYS and ChoiSJ. (2014). Optimization of the therapeutic efficacy of human umbilical cord blood–mesenchymal stromal cells in an NSG mouse xenograft model of graft-versus-host disease. Cytotherapy, 16:298–308.
46.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
47.
YuK-R, YangS-R, JungJ-W, KimH, KoK, HanDW, et al. (2012). CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells, 30:876–887.
48.
BartoshTJ, YlöstaloJH, MohammadipoorA, BazhanovN, CobleK, ClaypoolK, et al. (2010). Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci U S A, 107:13724–13729.
49.
StatonCA, ReedMWR and BrownNJ. (2009). A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol, 90:195–221.
50.
van SuylenRJ, AartsenWM, SmitsJF and DaemenMJ. (2001). Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med, 163:1241–1245.
51.
MinaminoT, ChristouH, HsiehCM, LiuY, DhawanV, AbrahamNG, et al. (2001). Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A, 98:8798–8803.
52.
ShinDM, Zuba-SurmaEK, WuW, RatajczakJ, WysoczynskiM, RatajczakMZ, et al. (2009). Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4+very small embryonic-like stem cells. Leukemia, 23:2042–2051.
53.
BaeSH, LeeHS, KangMS, StruppBJ, ChoppM and MoonJ. (2012). The levels of pro-inflammatory factors are significantly decreased in cerebral palsy patients following an allogeneic umbilical cord blood cell transplant. Int J Stem Cells, 5:31–38.
54.
ChengAS and YauTM. (2008). Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg, 20:94–101.
55.
MaltaisS, TremblayJ, PerraultL and LyH. (2010). The paracrine effect: pivotal mechanism in cell-based cardiac repair. J Cardiovasc Transl Res, 3:652–662.
56.
GharaibehB, LavasaniM, CumminsJ and HuardJ. (2011). Terminal differentiation is not a major determinant for the success of stem cell therapy—cross-talk between muscle-derived stem cells and host cells. Stem Cell Res Ther, 2:31.
57.
BartoshTJ, YlöstaloJH, BazhanovN, KuhlmanJ and ProckopDJ. (2013). Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1). Stem Cells, 31:2443–2456.
58.
LeeC, MitsialisSA, AslamM, VitaliSH, VergadiE, KonstantinouG, et al. (2012). Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation, 126:2601–2611.
ZhaoYD, CourtmanDW, DengY, KugathasanL, ZhangQ and StewartDJ. (2005). Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res, 96:442–450.
61.
AngeliniA, CastellaniC, RavaraB, FranzinC, PozzobonM, TavanoR, et al. (2011). Stem-cell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process. J Heart Lung Transplant, 30:1281–1293.
62.
OtaH, BeutzMA, ItoM, AbeK, OkaM and McMurtryIF. (2011). S1P4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm Circ, 1:399–404.
63.
BarkholtL, FloryE, JekerleV, Lucas-SamuelS, AhnertP, BissetL, et al. (2013). Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy, 15:753–759.
64.
JonesGN, MoschidouD, LayK, AbdulrazzakH, VanleeneM, ShefelbineSJ, et al. (2012). Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Stem Cells Transl Med, 1:70–78.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
